Cytomegalovirus therapy: Current constraints and future opportunities

Current Opinion in Infectious Diseases

Volumn 14, Issue 6, 2001, Pages 765-768

  Griffiths, Paul D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; GANCICLOVIR; NUCLEOSIDE ANALOG; VALACICLOVIR;

ANTIVIRAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG SAFETY; FUTUROLOGY; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; PATHOGENESIS; REVIEW; STRAIN DIFFERENCE; VIRUS REPLICATION;

EID: 0035215411     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200112000-00016     Document Type: Review

References (31)

1. Workshop of CMV disease: Definitions, clinical severity scores, and new syndromes
2. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation
3. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
4. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
5. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
6. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial
7. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
8. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
10. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
11. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
12. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation
13. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation
14. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation
15. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
16. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
17. The dynamics of human cytomegalovirus replication in vivo
18. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
19. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
20. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy
21. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy
22. When can cytomegalovirus prophylaxis and maintenance therapy be stopped in HIV disease?
23. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
24. Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis
25. CMV PCR viraemia in patients receiving ganciclovir maintenance therapy for retinitis: Correlation with disease in other organs, progression of retinitis and appearance of resistance
26. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
27. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance
28. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
29. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
30. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections
31. The economic impact of cytomegalovirus infection after liver transplantation